Leimang Bio reports low-dose metabolic CAR-T therapy results and cost targets
Overview
Leimang Bio vice president Tong Duyue tells Leiphone AI Tech Review that the company's metabolism-enhanced CAR-T therapy uses 1‰ of the standard dose and has produced a 100% complete response in dozens of patients with relapsed or refractory hematologic cancers and lupus.
The company says manufacturing cost is now under 100,000 yuan and it aims to go below 50,000 yuan. Leimang has two FDA IND approvals and three CDE IND clearances and plans to start Phase I clinical trials for hematologic and autoimmune indications.
These efficacy and cost figures are company claims reported in an interview, and no independent trial data is cited in the report.
Written by AI from the articles below · updated Nov 2, 4:28 AM ET
Check the sources:
Article timeline
The articles in this story. Times are ET.
- LeiphoneNewsLeiphone interviews Leimang Bio on low-dose CAR-T at 1‰ of standard dose
AILeiphone AI Tech Review interviews Leimang Bio vice president Tong Duyue about its metabolism-enhanced CAR-T therapy, which uses 1‰ of the standard dose. The company reports 100% complete response in dozens of relapsed or refractory hematologic cancer and lupus patients, and says it has cut manufacturing cost to under 100,000 yuan, with a goal below 50,000 yuan. Leimang has received two FDA IND approvals and three CDE IND clearances, and plans to begin clinical Phase I for hematologic and autoimmune indications.
Heat Trend
- Current comparable heat
- 7
- Peak comparable heat
- 9Nov 2, 5:00 AM ET
- Change in past 24 hours
- –
The trend compares only continuously observed participants, so its scope may be smaller than the current heat total. Hover or tap for hourly heat; use arrow keys with a keyboard.